Clinical Report: Clinical Characteristics and Treatment Approaches in Colombian Patients with Second Relapse of Multiple Myeloma

Overview

This study examines the clinical characteristics and treatment patterns of Colombian patients with multiple myeloma experiencing a second relapse. It reports an overall response rate of 47.1% and a median overall survival of 27.5 months.

Background

Multiple myeloma (MM) is a significant health concern, accounting for a notable percentage of cancer diagnoses and deaths globally. In Latin America, disparities in access to care and treatment options contribute to poorer survival outcomes compared to high-income countries. Understanding treatment patterns and outcomes in this region is crucial for addressing these inequities.

Data Highlights

Key Findings

• The study included 84 patients with a median age of 63.5 years.
• First-line therapy was predominantly bortezomib-based, with 36.9% receiving bortezomib, cyclophosphamide, and dexamethasone.
• Second-line treatment shifted towards lenalidomide-based regimens, administered to 29.8% of patients.
• Third-line treatments included novel agent-based combinations, notably with daratumumab and carfilzomib.
• The median overall survival from second relapse treatment initiation was 27.5 months.
• Adverse events were reported in 11.9% of patients, primarily of moderate severity.

Clinical Implications

The findings provide insights into treatment patterns in Colombian patients with multiple myeloma at second relapse.

Conclusion

This study provides data on the treatment landscape for multiple myeloma in Colombia, highlighting the effectiveness of third-line therapies.

Related Resources & Content

1. Blood Cancer Journal, 2022 -- Clinical Characteristics and Treatment Approaches in Colombian Patients with Second Relapse of Multiple Myeloma
2. Blood Cancer Journal, 2021 -- Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression
3. The ASCO Post, 2013 -- New Strategies for Relapsed/Refractory Multiple Myeloma Explored
4. NCCN GUIDELINES® INSIGHTS, 2025 -- Multiple Myeloma
5. Blood Cancer Journal — Clinical Characteristics and Treatment Outcomes in Newly Diagnosed Multiple Myeloma Patients in China: Findings from a Multicenter Study
6. CE NCCN GUIDELINES® INSIGHTS Multiple Myeloma, Ver
7. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - PubMed
8. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma | New England Journal of Medicine